SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending after recently securing FDA approval for AQVESME, making it the sole approved treatment for alpha- or beta-thalassemia. This significant regulatory win is driving broad conversation, though community perspectives are mixed, with some noting a dip in shares and discussing the implications of a required REMS program, while analysts have raised price targets.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending following the FDA approval of YARTEMLEA, its first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA). Investors are celebrating this significant milestone, anticipating substantial upside potential given the drug's unique market position and the company's strengthened financial outlook from a major licensing deal. The community is actively discussing a potential re-rating of the stock and speculation around a possible acquisition.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as the community discusses its approaching max circulating supply, anticipating a significant supply shock and potential for upward movement. This bullish outlook is heavily contested by concerns over the Compound Foundation's financial runway and ongoing governance challenges, leading to highly polarized views on its future in the decentralized finance landscape. Many compare its trajectory unfavorably to competitors like AAVE, highlighting deep divisions within the community.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is actively trending as the community weighs a proposed tokenomics redesign aimed at transitioning from inflationary staking rewards to a revenue-based model, hoping to enhance long-term value. While some anticipate a crypto-wide rally and see current prices as a buying opportunity, many remain concerned about its historical price performance and ongoing comparisons to newer, high-throughput, compliance-focused blockchain infrastructure.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is seeing a significant surge and high trading volume following the announcement that Sanofi will acquire the company for $15.50 per share in cash to bolster its adult immunization portfolio. While many long-term shareholders are celebrating much-anticipated gains, a notable segment of the community expresses disappointment, believing the offer undervalues the company given its vaccine assets and prior market discussions. This acquisition brings to a head ongoing conversations about the company's valuation and strategic direction.

Sprott Funds Trust. - Sprott Copper Miners ETF

The Sprott Copper Miners ETF ($COPP) is trending as discussions intensify around a potential copper supercycle, driven by increasing demand for the critical metal in AI and electrification. The community is actively debating the impact of possible US import tariffs on copper prices and whether this signifies a sustained bullish trend for the commodity.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos (XTZ) is gaining attention due to its Etherlink L2 receiving a fintech innovation award for a 'Uranium Tokenization Breakthrough,' showcasing its strategic pivot towards Real World Assets. This news, alongside increased staking accessibility, has ignited a fierce debate within the community, with some anticipating a significant turnaround while a vocal opposing segment views the asset as a 'sucker coin' burdened by an ever-increasing supply.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently trending as a leading bank stock, driven by significant regulatory progress and ongoing strategic initiatives, including a major wealth management partnership and advancements in digital assets. The community is actively discussing its substantial price appreciation and perceived undervaluation, while some caution about its rapid ascent and overbought technical indicators.

Philip Morris International, Inc. is a holding company, which engages in the business of delivering a smoke-free future and evolving a portfolio for the long term to include products outside of the tobacco and nicotine sector. It operates through the following geographical segments: Europe Region (Europe), South and Southeast Asia, Commonwealth of Independent States, Middle East, and Africa Region (SSEA, CIS, and MEA), East Asia, Australia, and PMI Duty Free Region (EA, AU, and PMI DF), and Americas Region (Americas). The Europe segment includes all the European Union countries, Switzerland, the United Kingdom, Ukraine, Moldova, and Southeast Europe. The SSEA, CIS, and MEA segment focuses on South and Southeast Asia, the African continent, the Middle East, Turkey, Israel, Central Asia, Caucasus, and Russia. The EA, AU, and PMI DF segment is involved in the consolidation of international duty-free business with East Asia and Australia. The Americas segment is comprised of the United States, Canada, and Latin America. The company was founded by Philip Morris in 1847 and is headquartered in Stamford, CT.

Philip Morris International Inc

Philip Morris International is gaining significant traction from its rapidly expanding smoke-free product portfolio, particularly IQOS and ZYN, driving strong financial performance. The company's strategic pivot away from traditional combustibles, coupled with recent regulatory news regarding expedited nicotine pouch reviews, is fueling market conversation. Community discussion highlights PM as a defensive growth opportunity, though some debate the sustainability of ZYN's momentum and the market's reaction to earnings reports.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO (RAVE CRYPTO) is a trending topic, primarily fueled by a news report detailing Trumps World Liberty Financial's integration of Aster Trade into its USD1 expansion, coinciding with the RAVE token achieving a record high. The community is actively discussing its breakout potential, with many expressing enthusiasm to participate in what they view as a significant rally and a potential for substantial upside, noting considerable recent trading volume.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates

Veeva (VEEV) delivered earnings and revenue surprises of +4.74% and +2.80%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of +43.48% and -31.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of +29.69% and -7.81%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.85% and -79.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates

Bioventus (BVS) delivered earnings and revenue surprises of -4.55% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Indivior PLC (INDV) Tops Q2 Earnings and Revenue Estimates

Indivior (INDV) delivered earnings and revenue surprises of +96.15% and +22.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates

Shares of CASI Pharmaceuticals, Inc. (CASI) traded 5% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6899273834937655">announced</a> that it has received a buyout proposal valuing the company’s operations in China at $20 million.The proposal, dated April 2, was put forth by company CEO Wei-Wu He and covers the company’s entire business operations in China and all license-in, distribution, and related rights in Asia, excluding Japan, related to certain pipeline products.CASI said the proposal updates the preliminary non-binding proposal letter submitted by He to the company on June 21, 2024.The company said that its special committee of the board of directors will evaluate the proposed transaction. However, no decisions have been made regarding the proposal letter or any alternative strategic option the company may pursue. &nbsp;The company added that there is no assurance that any definitive agreement relating to the proposal letter will be entered between the company and its CEO.On Stocktwits, retail sentiment about CASI Pharmaceuticals dipped slightly within the ‘extremely bullish’ territory (94/100), accompanied by a slight drop in message volume over the past 24 hours.<figure class="image"><img style="aspect-ratio:654/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_1_58_58_PM_png_20cfaa728f.webp" alt="CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits" width="654" height="149"><figcaption>CASI's Sentiment Meter and Message Volume as of 2:00 p.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> Late last month, CASI Pharma reported full-year 2024 revenue of $28.5 million, a decrease of 16% compared to 2023. The company noted that it was impacted by intensified competition and increased pricing pressure during the year.Net loss for the year came in at $39.3 million, higher than the $26.3 million reported in 2023.The company added that it had cash and cash equivalents of $13.5 million as of the end of 2024, less than the $29.1 million as of 2023-end.<a href="https://stocktwits.com/symbol/CASI">CASI shares</a> are down by over 25% this year and over 30% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/gm-marks-marginal-sales-growth-in-china-in-q1/chf7IpJRbeZ">GM Marks Marginal Sales Growth In China In Q1: But Retail Continues To Stay Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish

The company said that its special committee of the board of directors will evaluate the proposed transaction.

Equity

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

CASI
CASI Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASI News

CASICASI Pharmaceuticals Inc